Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.

Trial Details

NCT ID
NCT07479797
Phase
PHASE3
Sponsor
Kite, A Gilead Company
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • KITE-753
  • Axicabtagene Ciloleucel
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Duarte, California, United States|34.13945,-117.97729
  • Stanford, California, United States|37.42411,-122.16608
  • Denver, Colorado, United States|39.73915,-104.9847
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Individuals with any of the following large B-cell lymphomas, as determined by the investigator, are eligible for the study as defined below:
  • World Health Organization (WHO):
  • Individuals with chemorefractory disease to first-line therapy (primary refractory disease) that satisfies any of the following criteria:
  • Progressive disease (PD) and/or Deauville score of 5 (irrespective of the response designation) as the best response during the first-line treatmen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →